Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
- Ferreri, Andrés J. M
- Cwynarski, Kate
- Pulczynski, Elisa
- Ponzoni, Maurilio
- Deckert, Martina
- Politi, Letterio S
- Torri, Valter
- Fox, Christopher P
- Rosée, Paul La
- Schorb, Elisabeth
- Roth, Alexander
- Hemmaway, Claire
- Ferrari, Angela
- Linton, Kim M
- Rudà, Roberta
- Binder, Mascha
- Pukrop, Tobias
- Balzarotti, Monica
- Fabbri, Alberto
- Johnson, Peter
- Gørløv, Jette Sønderskov
- Hess, Georg
- Panse, Jens
- Pisani, Francesco
- Tucci, Alessandra
- Stilgenbauer, Stephan
- Hertenstein, Bernd
- Keller, Ulrich
- Krause, Stefan W
- Levis, Alessandro
- Schmoll, Hans J
- Cavalli, Franco
- Finke, Jürgen
- Reni, Michele
- Zucca, Emanuele
- Illerhaus, Gerald
- AMBROSETTI, Achille
DOIAbstract
Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk of haematological or neurological toxicity. In this trial, we addressed the tolerability and efficacy of adding rituximab with or without thiotepa to methotrexate-cytarabine combination therapy (the MATRix regimen), followed by a second randomisation comparing consolidation with whole-brain radiotherapy or autologous stem cell transplantation in patients with primary CNS lymphoma. We report the results of the first randomisation in this Article
Add to ORKG